Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
-
REGULATORY MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
-
REGULATORY Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
February 16, 2026
-
REGULATORY DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
-
BUSINESS FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
-
BUSINESS Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
-
BUSINESS Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
-
REGULATORY LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
-
COMMENTARY Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
-
ORGANIZATION Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
-
BUSINESS Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
-
BUSINESS Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
February 6, 2026
-
COMMENTARY Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
-
BUSINESS Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
-
BUSINESS Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
-
ORGANIZATION FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
-
BUSINESS AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
-
BUSINESS Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement
February 2, 2026
-
BUSINESS Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
-
REGULATORY Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…